Oklo Secures First NRC License, Advances Isotope Production
Event summary
- Oklo Inc. subsidiary Atomic Alchemy received its first NRC materials license on March 17, 2026.
- The license authorizes handling, processing, and distribution of up to 2 Curies of Ra-226, along with sealed sources of Co-60 and Am-241.
- Atomic Alchemy’s Idaho Radiochemistry Laboratory will process isotopes, initially recovering material from disused radium sources.
- The license supports Oklo’s plans for a multi-reactor isotope foundry with up to four 15 MWth Versatile Isotope Production Reactor (VIPR) systems.
The big picture
This license marks a significant step for Oklo, moving beyond design and planning into tangible execution within the nuclear sector. The increasing demand for isotopes, particularly for medical applications like targeted alpha therapy, highlights a strategic opportunity for domestic production to reduce reliance on foreign sources. Oklo’s entry into isotope processing positions it to benefit from a market currently constrained by limited U.S. supply chains and potentially high import costs.
What we're watching
- Regulatory Headwinds
- The speed of future NRC approvals for Oklo’s broader isotope production plans will be a key indicator of the company’s ability to scale operations and meet growing demand.
- Execution Risk
- The success of Atomic Alchemy’s processes and procedures, developed through laboratory experience, will be critical for the eventual deployment and efficiency of the planned isotope foundry.
- Market Dynamics
- How effectively Oklo can secure contracts and establish a reliable distribution network for its isotopes will determine its ability to capitalize on the rising demand and limited domestic supply.
Related topics